# Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome

> **NCT07737769** · PHASE1 · NOT_YET_RECRUITING · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 20 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Arsenic Trioxide
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Biopsy
- **DRUG:** Busulfan
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT07737769
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11
- **Primary completion:** 2028-11
- **Final completion:** 2029-11
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07737769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07737769, "Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07737769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*